Redica Systems

Conference Spotlight

Avoiding and Reacting to Human Tissue, Cell, and Gene Therapy Enforcement Actions: Communication is Key

May 7, 2020

Enforcement

FDA Warning Letters Week of 4/27/2020: HCT/P

May 6, 2020

Enforcement

Roundup of Q1 2020 Food and Dietary Supplement Warning Letters

April 29, 2020

Enforcement

Warning Letters Week of 4/20/2020: Untitled Letter to Stem Cell Firm

April 27, 2020

Part 2: Analysis of FDA FY2019 Drug GMP Warning Letters

April 23, 2020

Human Cell and Tissue Therapy Enforcement Actions Target Unapproved New Products Making Unsubstantiated Claims

April 23, 2020

Enforcement

Warning Letters Week of 4/13/2020: Compounding Pharmacy

April 21, 2020

Deploying Risk-Based Thinking within Management Systems

April 16, 2020

Enforcement

FDA Warning Letters Week of 4/6/2020: Devices, BIMO

April 14, 2020

March 483s: Most Popular and Newsworthy

April 9, 2020

Trends

Did COVID-19 Kill Just-in-Time Pharma Supply Chains?

April 9, 2020

Enforcement

FDA Warning Letters Week of 3/30/2020: Pharma, Device, GLP, and Compounding Pharmacy

April 7, 2020

CDRH Reorganization Takes a Total Product Lifecycle Approach; MDSAP, ISO Adoption, and Collaboration with MDIC Moving Forward

April 2, 2020

Enforcement

FDA Warning Letters Week of 3/22/2020: OTC and HCT/P

March 31, 2020

Enforcement

EMA Announcements Regarding Nitrosamine and MDRs

March 27, 2020

Big Pharma Puts Patients First in Response to COVID-19 Challenges; Collaboration with Regulators is Essential Going Forward

March 23, 2020

FDA Warning Letters Week of 3/8/2020: BIMO and OTC Products

March 17, 2020

Enforcement

COVID-19 Briefing: Covington & Burling Teleconference

March 17, 2020